 |
|
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Imane El Dika, Ghassan K. Abou-Alfa
Clin Mol Hepatol. 2017;23(4):273-279. Published online 2017 Nov 20 DOI: https://doi.org/10.3350/cmh.2017.0108
|
|
Citations to this article as recorded by
 Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex
Snehal K. Shukla, Mimansa Goyal, Dipti D. Kanabar, Seyoum Ayehunie, Bhavesh Deore, Carlos A. Sanhueza, Aaron Muth, Vivek Gupta
Journal of Molecular Liquids.2024; 401: 124701. CrossRef Construction of a Novel Diagnostic Model Based on Ferroptosis-Related Genes for Hepatocellular Carcinoma Using Machine and Deep Learning Methods
Shiming Yi, Chunlei Zhang, Ming Li, Jiafeng Wang, Zhongjie Shi
Journal of Oncology.2023; 2023: 1. CrossRef Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis
Zhaoxia Sun, Li Zhao, Shuang Wang, Honggang Wang
Annals of Hepatology.2022; 27: 100571. CrossRef Remifentanil reduces the proliferation, migration and invasion of HCC cells via lncRNA NBR2/miR‐650/TIMP3 axis
Wei Liang, Jinyuan Ke
International Journal of Experimental Pathology.2022; 103(2): 44. CrossRef Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
BMC Gastroenterology.2022;[Epub] CrossRef The pathogenesis of liver cancer and the therapeutic potential of bioactive substances
Song Gao, Xingyue Jiang, Liang Wang, Shanshan Jiang, Hanyuan Luo, Yan Chen, Cheng Peng
Frontiers in Pharmacology.2022;[Epub] CrossRef Potential Therapeutic Strategies to Combat HCC
Sidra Altaf, Faiza Saleem, Azam Ali Sher, Ashiq Ali
Current Molecular Pharmacology.2022; 15(7): 929. CrossRef Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells
Tae Ho Hong, M. T. Jeena, Ok-Hee Kim, Kee-Hwan Kim, Ho Joong Choi, Kyung Hee Lee, Ha-Eun Hong, Ja-Hyoung Ryu, Say-June Kim
Scientific Reports.2021;[Epub] CrossRef Long Non-coding RNA MAFG-AS1 Promotes Cell Proliferation, Migration, and EMT by miR-3196/STRN4 in Drug-Resistant Cells of Liver Cancer
Tianming Chen, Bin Huang, Yaozhen Pan
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Cancers.2021; 14(1): 67. CrossRef Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
Myung Ji Goh, Joo Hyun Oh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Liver Cancer.2021; 10(1): 52. CrossRef Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon
International Journal of Molecular Sciences.2020; 21(2): 472. CrossRef Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients
Kang Hyun Park, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung Chul Yoo, Jin Ho Hwang, Sang Woo Park, Young Jun Kim, Hee Sun Park, Mi Hye Yu, Hae Jeong Jeon
The Korean Journal of Gastroenterology.2020; 75(3): 147. CrossRef Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients” Jiayi Zhu, Yanling Huang, Jiquan Zhang, Yi Feng, Lan Shen
Drug Design, Development and Therapy.2020; Volume 14: 1481. CrossRef EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
Dong Jun Park, Pil Soo Sung, Jung-Hee Kim, Gil Won Lee, Jeong Won Jang, Eun Sun Jung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Journal for ImmunoTherapy of Cancer.2020; 8(1): e000301. CrossRef Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clinical and Molecular Hepatology.2020; 26(3): 328. CrossRef Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
Pil Soo Sung, Sung Woo Cho, Jaejun Lee, Hyun Yang, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Journal of Liver Cancer.2020; 20(2): 128. CrossRef The disubstituted adamantyl derivative LW1564 inhibits the growth of cancer cells by targeting mitochondrial respiration and reducing hypoxia-inducible factor (HIF)-1α accumulation
Inhyub Kim, Minkyoung Kim, Min Kyung Park, Ravi Naik, Jae Hyung Park, Bo-Kyung Kim, Yongseok Choi, Kwan Young Chang, Misun Won, Hyun Seung Ban, Kyeong Lee
Experimental & Molecular Medicine.2020; 52(11): 1845. CrossRef Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
Ya Li, Qiuju Han, Huajun Zhao, Quanjuan Guo, Jian Zhang
Frontiers in Pharmacology.2020;[Epub] CrossRef Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma
Hee Chul Nam, Pil Soo Sung, Do Seon Song, Jung Hyun Kwon, Soon Woo Nam, Dong Jin Yoon, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Seok Whan Moon, Hong Seok Jang, Jae-Sung Park, Sin-Soo Jeun, Yong-Kil Hong, Si Hyun Bae
International Journal of Clinical Oncology.2019; 24(6): 666. CrossRef Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Young Eun Chon, Hana Park, Hye Kyung Hyun, Yeonjung Ha, Mi Na Kim, Beom Kyung Kim, Joo Ho Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Seong Gyu Hwang, Kwang-Hyub Han, Kyu Sung Rim, Jun Yong Park
Cancers.2019; 11(4): 509. CrossRef Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis
David Sooik Kim, Tae Seop Lim, Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Oidov Baatarkhuu, Seung Up Kim
Digestive Diseases and Sciences.2019; 64(12): 3660. CrossRef Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang
Cancer Chemotherapy and Pharmacology.2019; 84(4): 809. CrossRef Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization
Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
Digestive Diseases and Sciences.2018; 63(4): 1062. CrossRef LncRNA NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363
Hai Huang, Jie Chen, Cheng‐Ming Ding, Xin Jin, Ze‐Ming Jia, Jian Peng
Journal of Cellular and Molecular Medicine.2018; 22(6): 3238. CrossRef Why develop photoactivated chemotherapy?
Sylvestre Bonnet
Dalton Transactions.2018; 47(31): 10330. CrossRef
|